MALVERN, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 93,000 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 15,600 shares of common stock to six hired employees. The stock options and RSUs were granted as of November 16, 2021, as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). Read More >>